Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 :97 –106.
Breman JG, 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64 :1–11.
Moorthy VS, Good MF, Hill AV, 2004. Malaria vaccine developments. Lancet 363 :150–156.
Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, Kester KE, Lanar DE, Lyon J, Hill AV, Pan W, Cohen JD, 2004. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71 :239–247.
Sina B, 2002. Focus on Plasmodium vivax.Trends Parasitol 18 :287–289.
Wertheimer SP, Barnwell JW, 1989. Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein. Exp Parasitol 69 :340–350.
Fang XD, Kaslow DC, Adams JH, Miller LH, 1991. Cloning of the Plasmodium vivax Duffy receptor. Mol Biochem Parasitol 44 :125–132.
Adams JH, Hudson DE, Torii M, Ward GE, Wellems TE, Aikawa M, Miller LH, 1990. The Duffy receptor family of Plasmodium knowlesi is located within the micronemes of invasive malaria merozoites. Cell 63 :141–153.
Sim BK, Toyoshima T, Haynes JD, Aikawa M, 1992. Localization of the 175-kilodalton erythrocyte binding antigen in micronemes of Plasmodium falciparum merozoites. Mol Biochem Parasitol 51 :157–159.
Miller LH, Mason SJ, Clyde DF, McGinniss MH, 1976. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295 :302–304.
Chitnis CE, Miller LH, 1994. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 180 :497–506.
Cole-Tobian J, King CL, 2003. Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol Biochem Parasitol 127 :121–132.
Michon P, Fraser T, Adams JH, 2000. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect Immun 68 :3164–3171.
Galinski MR, Medina CC, Ingravallo P, Barnwell JW, 1992. A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell 69 :1213–1226.
Galinski MR, Xu M, Barnwell JW, 2000. Plasmodium vivax reticulocyte binding protein-2 (PvRBP-2) shares structural features with PvRBP-1 and the Plasmodium yoelii 235 kDa rhop-try protein family. Mol Biochem Parasitol 108 :257–262.
Galinski MR, Barnwell JW, 1996. Plasmodium vivax: merozoites, invasion of reticulocytes and considerations for vaccine development. Parasitol Today 12 :20–29.
Rayner JC, Galinski MR, Ingravallo P, Barnwell JW, 2000. Two Plasmodium falciparum genes express merozoite proteins that are related to Plasmodium vivax and Plasmodium yoelii adhesive proteins involved in host cell selection and invasion. Proc Natl Acad Sci U S A 97 :9648–9653.
Rayner JC, Vargas-Serrato E, Huber CS, Galinski MR, Barnwell JW, 2001. A Plasmodium falciparum homologue of Plasmodium vivax reticulocyte binding protein (PvRBP1) defines a trypsin-resistant erythrocyte invasion pathway. J Exp Med 194 :1571–1581.
Triglia T, Thompson J, Caruana SR, Delorenzi M, Speed T, Cowman AF, 2001. Identification of proteins from Plasmodium falciparum that are homologous to reticulocyte binding proteins in Plasmodium vivax.Infect Immun 69 :1084–1092.
Rayner JC, Tran TM, Corredor V, Huber CS, Barnwell JW, Galinski MR, 2005. Dramatic difference in diversity between Plasmodium falciparum and Plasmodium vivax reticulocyte binding-like genes. Am J Trop Med Hyg 72 :666–674.
Singh S, Pandey K, Chattopadhayay R, Yazdani SS, Lynn A, Bharadwaj A, Ranjan A, Chitnis C, 2001. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein. J Biol Chem 276 :17111–17116.
Bouharoun-Tayoun H, Druilhe P, 1992. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 60 :1473–1481.
Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chong-suphajaisiddhi T, Druilhe P, 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172 :1633–1641.
Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P, 1995. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182 :409–418.
Banic DM, de Oliveira-Ferreira J, Pratt-Riccio LR, Conseil V, Goncalves D, Fialho RR, Gras-Masse H, Daniel-Ribeiro CT, Camus D, 1998. Immune response and lack of immune response to Plasmodium falciparum P126 antigen and its amino-terminal repeat in malaria-infected humans. Am J Trop Med Hyg 58 :768–774.
Jacobson KC, Thurman J, Schmidt CM, Rickel E, Oliviera de Ferreira J, Ferreira-da-Cruz MF, Daniel-Ribeiro CT, Howard RF, 1998. A study of antibody and T cell recognition of rhoptry-associated protein-1 (RAP-1) and RAP-2 recombinant proteins and peptides of Plasmodium falciparum in migrants and residents of the state of Rondonia, Brazil. Am J Trop Med Hyg 59 :208–216.
Banic DM, Goldberg AC, Pratt-Riccio LR, De Oliveira-Ferreira J, Santos F, Gras-Masse H, Camus D, Kalil J, Daniel-Ribeiro CT, 2002. Human leukocyte antigen class II control of the immune response to p126-derived amino terminal peptide from Plasmodium falciparum.Am J Trop Med Hyg 66 :509–515.
Shute GT, 1988. The microscopic diagnosis of malaria. Wernsdorfer WH, McGregor SI, eds. Malaria: Principles and Practice of Malariology. New York: Churchill Livingstone, 781–814.
Guruprasad K, Reddy BV, Pandit MW, 1990. Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Eng 4 :155–161.
Michon PA, Arevalo-Herrera M, Fraser T, Herrera S, Adams JH, 1998. Serologic responses to recombinant Plasmodium vivax Duffy binding protein in a Colombian village. Am J Trop Med Hyg 59 :597–599.
Fraser T, Michon P, Barnwell JW, Noe AR, Al-Yaman F, Kaslow DC, Adams JH, 1997. Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect Immun 65 :2772–2777.
Xainli J, Cole-Tobian JL, Baisor M, Kastens W, Bockarie M, Yazdani SS, Chitnis CE, Adams JH, King CL, 2003. Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect Immun 71 :2508–2515.
Camargo LM, Noronha E, Salcedo JM, Dutra AP, Krieger H, Pereira da Silva LH, Camargo EP, 1999. The epidemiology of malaria in Rondonia (Western Amazon region, Brazil): study of a riverine population. Acta Trop 72 :1–11.
Salcedo JM, Camargo EP, Krieger H, Silva LH, Camargo LM, 2000. Malaria control in an agro-industrial settlement of Rondonia (Western Amazon region, Brazil). Mem Inst Oswaldo Cruz 95 :139–145.
Singer BH, de Castro MC, 2001. Agricultural colonization and malaria on the Amazon frontier. Ann N Y Acad Sci 954 :184–222.
Oliveira-Ferreira J, Nakaie CR, Daniel-Ribeiro C, 1992. Low frequency of anti- Plasmodium falciparum circumsporozoite repeat antibodies and rate of high malaria transmission in endemic areas of Rondonia State in northwestern Brazil. Am J Trop Med Hyg 46 :720–726.
Mertens F, Levitus G, Camargo LM, Ferreira MU, Dutra AP, Del Portillo HA, 1993. Longitudinal study of naturally acquired humoral immune responses against the merozoite surface protein 1 of Plasmodium vivax in patients from Rondonia, Brazil. Am J Trop Med Hyg 49 :383–392.
Ferreira MU, Kimura ES, Camargo LM, Alexandre CO, da Silva LH, Katzin AM, 1994. Antibody response against Plasmodium falciparum exoantigens and somatic antigens: a longitudinal survey in a rural community in Rondonia, western Brazilian Amazon. Acta Trop 57 :35–46.
Levitus G, Mertens F, Speranca MA, Camargo LM, Ferreira MU, del Portillo HA, 1994. Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax.Am J Trop Med Hyg 51 :68–76.
Balthazar-Guedes HC, Ferreira-Da-Cruz MF, Montenegro-James S, Daniel-Ribeiro CT, 1995. Malaria diagnosis: identification of an anti-40-kDa polypeptide antibody response associated with active or recent infection and study of the IgG/IgM ratio of antibodies to blood-stage Plasmodium falciparum antigens. Parasitol Res 81 :305–309.
Ferreira-da-Cruz MF, Deslandes DC, Oliveira-Ferreira J, Montenegro-James S, Tartar A, Druilhe P, Daniel-Ribeiro CT, 1995. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas. Parasite 2 :23–29.
Oliveira-Ferreira J, Pratt-Riccio LR, Arruda M, Santos F, Daniel Ribeiro CT, Carla Golberg A, Banic DM, 2004. HLA class II and antibody responses to circumsporozoite protein repeats of P. vivax (VK210, VK247 and P. vivax-like) in individuals naturally exposed to malaria. Acta Trop 92 :63–69.
Riley E, 1994. Malaria. Kierszenbaum F, ed. Parasitic Infections and the Immune System. San Diego: Academic Press, xii, 254.
Camargo EP, Alves F, Pereira da Silva LH, 1999. Symptomless Plasmodium vivax infections in native Amazonians. Lancet 353 :1415–1416.
Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP, 2002. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 66 :641–648.
Braga EM, Barros RM, Reis TA, Fontes CJ, Morais CG, Martins MS, Krettli AU, 2002. Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region. Am J Trop Med Hyg 66 :461–466.
Baird JK, 1998. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum.Ann Trop Med Parasitol 92 :367–390.
Druilhe P, Khusmith S, 1987. Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status. Infect Immun 55 :888–891.
Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P, 1994. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84 :1594–1602.
Nguer CM, Diallo TO, Diouf A, Tall A, Dieye A, Perraut R, Garraud O, 1997. Plasmodium falciparum- and merozoite surface protein 1-specific antibody isotype balance in immune Senegalese adults. Infect Immun 65 :4873–4876.
Taylor RR, Allen SJ, Greenwood BM, Riley EM, 1998. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 58 :406–413.
Druilhe P, Bouharoun-Tayoun H, 2002. Antibody-dependent cellular inhibition assay. Methods Mol Med 72 :529–534.
Kirchgatter K, del Portillo HA, 1998. Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a genetic marker. J Infect Dis 177 :511–515.
Soares IS, da Cunha MG, Silva MN, Souza JM, Del Portillo HA, Rodrigues MM, 1999. Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1. Am J Trop Med Hyg 60 :357–363.
Good MF, 2001. Towards a blood-stage vaccine for malaria: are we following all the leads? Nat Rev Immunol 1 :117–125.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||348||114||1|
Naturally acquired antibody reactivity to two major Plasmodium vivax vaccine candidates was investigated in 294 donors from three malaria-endemic communities of Rondônia state, Brazil. Antibody recognition of recombinantly expressed antigens covering five different regions of P. vivax reticulocyte binding protein 1 (PvRBP1) and region II of P. vivax Duffy binding protein (PvDBP-RII) were compared. Positive IgG responses to these antigens were significantly related to the level of malaria exposure in terms of past infections and years of residence in the endemic area when corrected for age. The highest prevalence of anti-PvRBP1 total IgG antibodies corresponded to the amino acid regions denoted PvRBP1431-748 (41%) and PvRBP1733-1407 (47%). Approximately one-fifth of positively responding sera had titers of at least 1:1,600. Total IgG responses to PvDBP-RII were more prevalent (67%), of greater magnitude, and acquired more rapidly than those to individual PvRBP1 antigens. Responses to both PvRBP1 and PvDBP-RII were biased toward the cytophilic subclasses IgG1 and IgG3. These data provide the first insights on acquired antibody responses to PvRBP1 and a comparative view with PvDBP-RII that may prove valuable for understanding protective immune responses to these two vaccine candidates as they are evaluated as components of multitarget blood-stage vaccines.